Webinars

Improving and Intensifying Vaccine Purification By Implementing Affinity Chromatography

This webcast features: Zoltan Gulyas, Field Applications Specialist, Thermo Fisher Scientific Vaccines are well-established tools in the fight to eradicate infectious diseases. Over the past few decades, vaccine production has advanced significantly, largely by the introduction of new molecule modalities. However, these new types of vaccine candidates often require multiple chromatographic steps to obtain the desired level of purity. Developing an efficient purification process using the classical surface chemistries such as ion exchange and hydrophobic interaction requires significant amounts of…

AAV Suspension Platform Generations: Continuous Improvement Leading to Increased Viral Vector Titer and Yield

This webcast features: Yiyu Dong, Head of Cell Line Development, and David Barnard, Senior Scientist, Process and Technology Development, WuXi Advanced Therapies The field of gene therapy has experienced significant growth in recent years. Adenoassociated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that increased viral vector…

Exploring New and Improved Analytical Methods for Traditional and Unique Modalities

This webcast features: Jason Sterling, Principal Scientist and Project Director, Analytical and Formulation Resources, and John Rockwell, Group Leader, Catalent Pharma Solutions Biophysical characterization is critical to understand the make-up and behaviors of biologic therapies and vaccines both early in development and throughout the manufacturing scale-up process. As biologics become more complex in structure, and as scientists improve their understanding of the effects of structure on stability, efficacy, safety, etc., there is a need to develop new and improved analytical…

Analytical Ultracentrifugation for Characterization of AAV Gene Delivery Vectors

This webcast features: Christopher Sucato, PhD, Associate Director, Biophysical Characterization, and Cynthia Swanson, Associate Research Scientist, Charles River Laboratories Analytical ultracentrifugation (AUC) has been a staple in the biopharmaceutical industry to analyze aggregation and higher-order structure in protein drug products. With the recent boom in cell and gene therapies using gene-delivery vectors, new avenues for AUC-based characterization and QC lot release methodologies are now available. View this webinar for a discussion on the new parameters of AUC analysis and how…

Opto-Sensor Guided Centrifugation for Efficient, Reagent-Free Cell Separation in a Semi-Automated Closed System

This webcast features: Ben Josey, PhD, Field Applications Scientist, Corning Life Sciences The potential for cell-based immunotherapies is moving fast. But some of the processes to develop and manufacture these clinical-grade therapies can slow you down. This Ask the Expert webinar will cover ways you can reduce the manual steps involved in traditional cell processing. Attend to learn more about: Tips to streamline cell separation and formulation of specific cell populations for cell and gene therapy development and manufacturing Ways…

De-Risking INDs with Unrivaled Monoclonality Assurance in Cell Line Development

This webcast features: Tanner Nevill, Vice President, Program Management, Berkeley Lights Monoclonality assurance is a central regulatory requirement for all cell lines manufacturing biologic therapies. Imaging is currently the gold standard for confirming that production cell lines originate from a single cell. However, conventional well plate imaging is very labor-intensive and prone to error due to the presence of “ghost” cells and debris that are difficult to differentiate from cells. Opto™ cell line development (CLD) on the Berkeley Lights Beacon® system provides…

How to Halve the Costs of Antibody Purification?

This webcast features: Romain Dabre, Senior Product Manager, Tosoh Bioscience Downstream processing is responsible for up to 80% of the entire production costs of biotherapeutics. Given the current drive to reduce manufacturing costs for biological therapeutics, streamlining downstream processing is necessary for chromatographers and process engineers. In this presentation, we showcase the benefits of using only two chromatography processes to purify monoclonal antibodies compared to the standard industrial process. Combining high-performance Protein A capturing and a single polishing step on salt-tolerant…

Best Practices for Ensuring High Virus Clearance When Using Anion Exchange Membrane Adsorbers

This webcast features: Sherri Dolan, Global Technology Consultant, Separations Marketing Group, Sartorius Stedim Biotech The risk of viral contamination is a concern for all biopharmaceuticals and vaccines derived from cell lines and can have serious implications. Contamination events can cost millions of dollars in investigation, clean-up, corrective action, and manufacturing plant downtime. Most importantly, such events pose a safety risk to the patient. To ensure the safety of biological products, regulatory agencies require manufacturing processes to have a validated current…

Configurable, Single-Use TFF Systems for Rapid Bioprocessing

This webcast features: David Serway, Global Director, Single-Use TFF Systems and ProConnex® Flow Paths, Repligen The explosive growth in biologics and gene therapies, the globalization of biomanufacturing, and the pressures to reduce capital investment and cost of goods while accelerating speed to market all point to changes in how bioprocessing systems/skids are designed, built, and operated. Future hardware, software, and consumables built on the principle of flexibility and extensive use of single-use, closed, complete, and ready-to-operate technologies will be described.…

Bioprocess Selection and Economics: 5,000-L DynaDrive™ Bioreactor Shifting the Paradigm

This webcast features: Jeff Johnson, Founder and President, BioTech Design, LLC, Mark Thomas Smith, R&D Engineer, Thermo Fisher Scientific, and Kevin Mullen, Senior Product Manager, Thermo Fisher Scientific Single-use technologies enable a flexibility and modularity effectively unattainable with more traditional stainless-steel technologies, particularly in upstream bioprocesses. Single-use bioreactors up to 2,000 L are employed largely in preclinical- and clinical-stage bioprocesses to leverage this flexibility. As products reach commercial maturity, scales larger than 2,000 L frequently become desirable to take advantage…